ESOC 2022 | Lack of evidence for hemostatic treatment for intracerebral hemorrhage

Thorsten Steiner, MD, PhD, Frankfurt Höchst Clinic, Frankfurt & Heidelberg University, Heidelberg, Germany, shares his thoughts on key topics to address in the field of intracerebral hemorrhage (ICH), highlighting the clinical benefits of hemostatic therapy as a major data gap. Hemostatic trials for ICH have failed to clearly show the benefit of prompt anticoagulation reversal, typically showing no significant effects on functional outcomes at 90 days. Given the substantial predictive value of hematoma volume for 30-day mortality after ICH, ultra-early hemostatic is considered best practice to prevent hematoma expansion, until further data are available. This interview took place at the ESOC 2022 congress in Lyon, France.